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PROTON QUEST: A BIOTECH GROUP
1. BACKGROUND AND STRUCTURE
Proton Quest and its two main divisions – introduction
Proton Quest, a European biotechnology (biotech) group, was founded in 1989 and obtained a
listing on a European Stock Exchange in 1994. It was founded by the current Chief Executive
Officer (CEO), Dr Martin Hislop, and his former biochemistry tutor, Professor Sergio Martinez.
Proton Quest is unique in that it does not seek independently to discover or develop drugs; rather
it manages networks of university and commercial partners to develop the discovery of new
compounds. In short, Proton Quest is a typical biotech company in its embryonic stage,
experiencing identical challenges to those facing the industry as a whole.
Proton Quest has three quite striking features. First is its close links with academia. Second, the
group has two main divisions (see Appendix A): Molecular Allies and Techno Insights. The purpose
of the Molecular Allies division is to identify innovative discovery projects; it brings together and
manages virtual teams of scientists from universities and pharmaceutical companies to co-develop
individual projects. As for Techno Insights, it holds a leading position in software development for
drug discovery. Third, Proton Quest is unusual in the European biotechnology sector in having
achieved a net profit in 1998.
Software development
The group was originally established to develop and market software to manage the drug discovery
process. [The drug discovery process is briefly outlined in Appendix K (Table One).] Computer
technology had become increasingly important in the discovery of new drugs in the late 1980s.  Its
importance has been crucial during the 1990s and will continue into the twenty-first century.
Informatics1 is particularly important to the future of the pharmaceutical sector. Jan Leschy, the
CEO of (then) SmithKline Beecham, commented at a public lecture at City University in June
1998, that informatics, along with molecular and genetic diagnostics, are key to the future of both
his group and the industry as a whole. At the heart of Proton Quest's current range of software
products are Bio-informatics, Chemo-informatics and Computer Aided Molecular Design, which are
central to the informatics revolution (see Tables Two to Four in Appendix K for more details).
Proton Quest has been described by some analysts as the Microsoft of the drug discovery sector.
It certainly has ambitions to become the industry standard in this sector and has developed a
considerable established base inside both pharmaceutical and biotechnology companies. Dr
Hislop recently observed that:
"We {Proton Quest} want to make our software and services the industry standard through close
alliance with large international partners" (press quotation) and "You would be hard pressed to find
any pharmaceutical research establishment anywhere in the world that does not have Proton
Quest software at some level" (Top Five Consultants' report, 1998).
In fact, the group has developed many of its software products through on-site development with
leading pharmaceutical companies.
Success in software is only one aspect of Proton Quest's goal to be an industry standard. The
other critical aspect is provision of drug services. It is to this end that, in 1995, Proton Quest
                                                
1 For the purpose of this case, we define informatics as the application of computer tools to the drug
discovery process. Proton Quest’s tools aid researchers in the identification of targets to deal with an
illness, in the process of finding “lead compounds shown to be active against a biological target” and in
the process of refining a lead into a compound which enters regulatory clinical trials (Annual Report
1997).
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formally established its Molecular Allies division. This division brings together a diverse range of
skills which it offers, under contract, to pharmaceutical and biotechnology companies. The goal of
this division is to play a central role in the strategic development of the group "by winning and
managing drug discovery projects" (Annual Report 1997).
Market for outsourced specialist drug discovery IT (software) and drug discovery
research services
Table A
 Market  1996 Euros,
millions (em)
 2002 Euros,
millions (em)
 
% Growth
 Outsourced IT  500  1,300  160
 IT outsourcing available to Proton
Quest
 400  1,000  150
 Outsourced drug discovery research
projects
 900  2,200  144
 Total accessible market  1,300  3,200  146
 Source:  Proton Quest Annual Report 1997
2. MOLECULAR ALLIES DIVISION
The importance of the division
The Molecular Allies division is of critical importance to Proton Quest, and is viewed by the head of
this division, Dr Leonardo Vieira, as the future of the group.   Also, the Techno Insights division is
vitally important to Molecular Allies.
An intriguing aspect of the Molecular Allies division is that while it only had seven full-time staff by
the end of 1997, it generated sizeable proportions of the group's revenues in 1996 and in 1997.
This is despite the fact that Proton Quest employed 175 people in 1997 (Annual Report 1998). A
share price graph (Appendix B) depicts the level of investor confidence in Proton Quest.
An important reason for interest in the Molecular Allies division is that it has long-term potential.
Not only is there a built-in profit margin in each contract, there is also a profit-sharing element. If a
drug, which the division was involved in discovering, makes it to the marketplace, the customer is
required to give Proton Quest a small royalty payment on each sale. In the case of the Techno
Insights (software) division, products are sold to customers at a once-off profit margin.
Commenting on the software division, Dr Vieira observed that:
"As far as I am aware there are no deals done that involve royalties on drugs that may reach the
market. So they develop software and sell software products for a good deal."
The Molecular Allies division has aroused interest because of its long-term potential to generate
not only one half of the group's turnover, but also presents the possibility of achieving considerable
royalty payments. This would be bottom line revenue and, while the royalty would be a single
percentage point, it could still represent a sizeable return. As Dr Vieira noted:
"If you find a new asthma treatment or a new obesity treatment, which is something we are working
on for a current client, you are talking at least a billion (one thousand million) Euro drug, so a few
per cent is a few tens of millions of Euros."
The group believes that it can obtain a considerable share of the outsourced research market. Dr
Hislop stated that:
 "Proton Quest believes that the market for outsourced services {both IT and research} could
reach e2,200 million each year within 5 years. Proton Quest, in a synergistic alliance with its
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recently established partners, Molecules4U Combinations Ltd and Molecules4U Drug Discovery
Ltd, is well placed to take a significant share of this market" (Annual Report 1998).
According to a press report, Dr Hislop is aiming for Proton Quest to capture between 15% to 20%
of the total outsourcing market, which he predicts will have grown to e5,000 million by the year
2005. This would equate to corporate-wide sales of between e750 million and e1,000 million each
year. On the other hand, if Dr Vieira's prediction – that Molecular Allies will make up half of the
group's revenues within three years – occurs, then this division would have increased its turnover to
between e375 million and e500 million each year by 2005.
The group believes that to attack the biotech market effectively, it is essential to move forward on
both the software and services fronts. The 1997 Annual Report states that the overall strategic
intent of the group is:
"To be the world's leading supplier of drug discovery solutions through the integration of
information technology and drug discovery services including combinations chemistry, high
throughput screening and genomics".
Molecular Allies – business methodology
The Molecular Allies division seeks to integrate multiple forms of knowledge from within Proton
Quest, its network of partner companies, and university research sub-contractors to deliver high-
value, knowledge-intensive, drug discovery services to pharmaceutical and biotechnology
companies. In the context of Proton Quest, this division is of particular importance because of the
rapid internal growth predicted by Dr Vieira, the size of the potential external market, and the low
levels of staff required relative to turnover.  The group's strategy for Molecular Allies is developed
through alliances, for example, one alliance has been formed with a large Japanese
pharmaceutical company, Ionic Tiger, and another with a small, virtual, UK biotechnology group,
BioCell3.
The division has engaged in many major drug discovery projects. Nine of these projects (for which
there are details) are outlined in Appendix H. An important question to ask is "why do such
companies choose to outsource part of their research to Proton Quest?" In the case of the small
biotechnology companies, the answer is simple. It is because of a lack of financial, or physical,
resources and/or a lack of technical, or organisational, capabilities. As Dr Vieira put it:
"A small biotech {comes to us} because they don't have the know-how to do {a particular element
of the discovery process} internally and they don't have the cash to buy in that know-how internally
at their current resource level. They don't want to spend money on hiring somebody full time and
buying a computer and software to do it. It is cheaper to come to us and they can get to the next
stage of the discovery process more quickly."
The reasons why a large pharmaceutical company would be attracted to the Molecular Allies
division are more complex. It is not a question of a large pharmaceutical company lacking
knowledge about rational drug design, combinations chemistry, high throughput screening, or
management of projects across universities and commercial organisations. Large pharmaceutical
companies have all these skills, and where there are gaps in their knowledge pools, it would be
possible to buy them in, given their vast financial resources. Many of the larger companies spend
over e1 billion per year on research and development. Instead, Dr Vieira identifies three broad
reasons. The first two reasons essentially conform to the concept of strategic focus, while the third
conforms to the concept of technology options.
The first is "spill-overs". A unit within the pharmaceutical company may have an area which it
wishes to research, but because of other projects, it lacks time to commit internal resources to
the project.
Second, there are technological gaps which the pharmaceutical company is aware of and decides
it needs to fill. These may be specialist techniques which the company needs in order to complete
a single project, or alternatively which it needs to acquire and absorb into its future drug discovery
methodologies. To this end it may seek out a specialist group, such as Proton Quest, from which
it can fill the gap for a single project, and/or engage in technology transfer. Examples of this kind
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of collaboration would be the Panda Pharmaceuticals and Ionic Tiger projects where the Molecular
Allies division is not only managing the project, and providing specialist drug discovery services
such as computer aided molecular design (CAMD) and combinations chemistry, but is also
enabling these capabilities to be transferred to its clients through intensive reporting and on-site
training of the customer's staff.
Third is the search for new technologies. Essentially, the large pharmaceutical company engages
in a diverse range of alliances to explore new and emerging drug discovery technologies and
methodologies. Technology is moving very quickly and can be costly to implement. Through these
alliances, the pharmaceutical company is able to see the technology or methodology in action and
then decide whether it needs to develop this capability internally, or whether it is peripheral to its
strategic focus and can therefore be outsourced. When referring to these types of technology
search alliances, Dr Vieira commented that the pharmaceutical company:
"will want to hedge its bets and make sure that it goes for the right approach {technology or
methodology} and that is another reason for making sure that it allies with someone like our group
{which is involved at the frontiers of rational drug design, combinations chemistry, and high
throughput screening}."
So, essentially, collaborators choose Proton Quest to fill gaps in their technological capabilities,
with the aim of applying these to an individual project, or engaging in technology transfer.
The division's performance
Essentially there are three interconnected levels of success for the division. The first is that the
project attains its underlying scientific goals. These goals will have been determined at the start of
the project, though they may develop through a process of negotiation with the collaborative
partner during the evolution of the project.
Having achieved the basic scientific goals of the project, the second and third routes of success
are essentially outside the control of Proton Quest and are in the hands of the client. The second
route of success is to take a compound from discovery into drug development. Drug development
is an expensive process and for many reasons a client may decide not to enter a compound into
clinical trials. These reasons may not be because of a failure in the project on the part of Proton
Quest. As Dr Vieira notes:
"{To enter clinical trials you need} a compound that is not just active and selective, but has also
got all the usual animal-type properties. There are lots of different levels of success for us. A
partner's failure doesn't mean that we have failed."
The third route of success is where a drug makes it through the discovery and development
processes and into the marketplace. In this scenario Proton Quest, through the division, would
obtain single-figure royalties. When considering this possibility, Dr Vieira remains mindful that the
basic route of success for the group remains attainment of the underlying goals of the initial
discovery project. He comments that:
"If we meet our goals in a project, and that may be more than just designing an active compound,
then it is a success for us. There is another tier of success, where we get a drug to market and we
get a nice big royalty stream."
So has Proton Quest been successful to date?
On the first route of success the answer is yes. Collaborative partners are consistently paying
Proton Quest research fees for the work it does on their behalf. They would not do so if the
Molecular Allies division did not meet the scientific goals of the project.
On the second route the group also seems to have had some success. Its collaboration with
RXRibo on a radio-immunotherapy product was a success at the discovery stage. The product is
now in phase II clinical trials. Given that the discovery phase can take many years (Parexel
International (1996) estimated that on average it takes 3·3 years), it is not surprising that few of the
division's projects have entered clinical trials to date. There should be a clearer picture of the
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success of the division in discovering compounds which enter clinical trials after a period of several
years has elapsed.
It is probably fair to say that the long-term success of the division depends on managing projects
which enter clinical trials. After all, the remit of the division is drug discovery and the immediate
goal of that process is to discover compounds which can then enter clinical trials. The third route,
namely a drug entering the market, is not as critical to the long-term success of the group. The
reasons why a drug can fail clinical trials are varied, and where these can be managed they are
largely in the hands of the developer, not the discoverers.
The financial success of the division (Appendices F and G) is masked in Proton Quest's
unpublished accounts by the consolidation of the results of both the Techno Insights and
Molecular Allies divisions. As noted previously, the Molecular Allies division is delivering a
significant  proportion of the group's turnover, while consuming only a small number of the group's
internal staff resources.
Strategic direction – Molecular Allies
Unlike most of the entrepreneurial life science companies listed on European stock exchanges,
Proton Quest does not directly invest shareholders' funds in the independent discovery of novel
therapeutic compounds. As outlined earlier, it seeks to provide services to other companies in the
pursuit of this activity. Provision of software services is one route. The other is a more direct,
hands-on, participation in the drug discovery process, through provision of managerial or specialist
services.
The Molecular Allies division can provide customers with specialist technical services such as
protein analysis, antibody engineering, high throughput screening and quantitative structure activity
relationship services – to mention but a few. These projects are normally of a short duration and
are aimed at over-stretched drug design departments within pharmaceutical companies which are
looking to sub-contract specific projects, or companies that currently do not have access to these
types of skills and expertise in-house (source: Proton Quest).
The Molecular Allies division can also service higher level bespoke research projects in which it
plays both a managerial and technical role. These projects may be initiated by either the customer
or Proton Quest (or its divisions). For example, in the case of collaboration with Ionic Tiger
Pharmaceuticals, it was Molecular Allies which came up with the initial novel drug target, focusing
on Ion channels. It then sold this initial idea as a project to Ionic Tiger.  Molecular Allies manages
the project on Ionic Tiger's behalf in return for contract fees, milestone payments2, and a share of
future royalties. In the case of its collaboration with BioCell3, it was BioCell3 which came to Proton
Quest with a novel drug target.  It contracted the group to manage a project to identify and
optimise lead compounds which BioCell3 could then take into clinical trials. Again, Molecular
Allies receives research fees, milestone payments and future royalties.
In such projects, the Molecular Allies division brings with it a "wealth of experience and expertise
in target identification, screening, synthesis, molecular design and informatics" (Annual Report
1997). More importantly, it brings with it a network of contacts through which it can access the
skills of leading edge researchers. There are two strands to this network. The first is access to
university researchers. This is a key element of the division's original guiding principle.
3. PROTON QUEST'S PARTNER COMPANIES
The second important network is Proton Quest's two partner companies, Molecules4U
Combinations Ltd and Molecules4U Drug Discovery Ltd. The results of these two partner
companies are dealt with as trade investments in the accounts.  Dr Hislop sums up the
importance of these strategic partners, noting that:
                                                
 2 Milestone payments involve a collaborative partner making staged cash payments upon the
achievement of specific research milestones.
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"The combination of Proton Quest's software and drug design expertise, Molecules4U
Combinations' chemical synthesis skills and Molecules4U Drug Discovery's advanced screening
capabilities will provide customers with a highly cost-effective method of accelerating the drug
discovery process" (Proton Quest).
Proton Quest has built up its expertise in drug discovery software through internal growth and over
a dozen acquisitions. These acquisitions have brought with them new products, markets and
expertise. (The Molecular Allies division seems to be emulating this strategy to a lesser extent,
concentrating more on organic growth and its web of university sub-contractors.)  Nevertheless,
during 1997, Proton Quest was involved in establishing Molecules4U Combinations Ltd (see
Appendix I) and Molecules4U Drug Discovery Ltd (see Appendix J), taking a minority stake in both
companies, with options to buy outright.
The central importance of these companies in the long-term success of the Molecular Allies
division is stated in the 1998 Annual Report. It notes that if the group is to achieve its aim of being
a full drug discovery service provider, then it is important that it should have four core capabilities,
namely informatics, chemical libraries, biological screening and genomics.
Informatics is the central capability around which the others are presently organised. This
capability has been internally developed by Proton Quest. The 1997 Annual Report notes that the
Proton Quest group provides the essential informatics infrastructure that co-ordinates the scientific
team. The Molecular Allies division provides multi-disciplinary research project management and
expertise in lead identification and optimisation.
Expertise in chemical synthesis and combinations chemistry libraries is provided by Molecules4U
Combinations. Expertise in biological screening is provided by Molecules4U Drug Discovery.
The final key capability is genomics. When discussing the impact of genomics in a press
interview, Dr Hislop predicted that about 60% of the new drugs targets will emerge from these
disciplines.
Clearly this is an area which the group needs to address in the near future.
4. FURTHER CONSIDERATIONS
A major threat to the commercial success of small biotechnology companies, identified in a Top
Five Consultants' Report, is that of technology consolidation. The report warns that companies
relying on a single technological expertise will have grave difficulty in continuing to attract
pharmaceutical partner companies, from which they can extract high profit margins. However, the
Molecular Allies division has successfully expanded its technological expertise in informatics to a
broader range of technological capabilities through its virtual network. The future of the division
appears bright if it can build on its current technological capabilities, manage its network, and
expand its technological base to include a genomic capability.
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Appendix A
PROTON QUEST DIVISIONAL CHART
Divisions, Directors and Partner Companies
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Appendix B
Proton Quest Group share price graph for the period January 1996 to May 2001.
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Appendix C
Proton Quest
Balance sheets at 31 December 1996, 1997, 1998, 1999 and 2000
Unpublished Group Accounts
These accounts include all of Proton Quest's activities
1996 1997 1998 1999 2000
Actual Actual Actual Actual Actual
e000 e000 e000 e000 e000
Fixed assets:
Tangible assets 1,033 1,923 2,327 6,617 8,312
Intangible assets 0 0 0 32,488 22,473
Trade investments        0        0   9,263   8,665   4,293
1,033 1,923 11,590 47,770 35,078
Current assets:
Stock 262 208 73 267 453
Debtors 3,868 4,293 10,367 19,467 14,502
Investments 1,170 1,038 0 0 0
Cash at bank and in hand   4,998 13,392 32,612 12,138   5,965
10,298 18,931 43,052 31,872 20,920
Less: Current liabilities:
Trade creditors 1,552 1,400 1,455 2,625 4,488
Finance leases 112 75 65 50 1,855
Other creditors 1,793 397 988 1,565 1,925
Accruals and deferred income 4,432 4,680 7,448 10,260 14,730
Bank overdraft 0 0 0 780 0
Deferred cash consideration        0        0        0          0      145
7,889 6,552 9,956 15,280 23,143
Net current (liabilities)/assets 2,409 12,379 33,096 16,592 (2,223)
Total assets less current liabilities 3,442 14,302 44,686 64,362 32,855
Less: Creditors due after one year 132 160 25 757 3,645
Provision for liabilities and charges        0          0          0          0   9,020
Net assets 3,310 14,142 44,661 63,605 20,190
Called-up share capital 19,843 53,140 107,265 129,700 129,728
Reserves (16,533) (38,998) (62,604) (66,095) (109,538)
  3,310 14,142 44,661 63,605 20,190
Candidates should not attempt to reconcile the movement in reserves.
Notes:
 1. The change in intangible assets in year 2000 is because of an impairment charge and
amortisation of goodwill.
 2. The two partner companies began their relationship with Proton Quest on 1 January 1998.
FLCS pre-seen M200112
Appendix D
Proton Quest
Profit and loss accounts for the years ended 31 December 1996 –2000 (unpublished)
 These accounts include the trading operations of Molecular Allies and Techno Insights
1996 1997 1998 1999 2000
Actual Actual Actual Actual Actual
e000 e000 e000 e000 e000
Sales 10,298 16,315 26,068 35,842 32,933
Cost of sales (3,513) (4,188) (5,388) (6,135) (8,325)
Gross profit 6,785 12,127 20,680 29,707 24,608
Research & Development (2,898) (5,227) (8,237) (11,037) (12,428)
Administrative expenses (10,450) (10,767) (13,655) (22,127) (32,055)
EBIT (earnings before interest and tax)
(6,563) (3,867) (1,212) (3,457) (19,875)
Interest income 505 877 1,667 1,555 315
Interest expense     (97)     (92)   (28)    (145)      (388)
EBT (earnings before tax) (6,155) (3,082) 427 (2,047) (19,948)
Taxation payable    (112)    (208) (192)    (838)      262
Earnings after tax (6,267) (3,290) 235 (2,885) (19,686)
 
Appendix E
Proton Quest
Statement of cash flows 1996 – 2000  (unpublished)
These accounts include the trading operations of Molecular Allies and Techno Insights
1996 1997 1998 1999 2000
Actual Actual Actual Actual Actual
e000 e000 e000 e000 e000
EBIT (earnings before interest and tax) (6,563) (3,867) (1,212) (3,457) (19,875)
Interest income (expense)    408    785 1,639 1,410        (73)
Pre-tax profit (6,155) (3,082) 427 (2,047) (19,948)
Taxes    (112)    (208)    (192)    (838)      262
Net income (6,267) (3,290) 235 (2,885) (19,686)
Depreciation 480 653 823 1,640 4,432
Amortisation 0 0 0 1,700 10,015
Capital expenditures    (913)    (768)    (950) (1,867) (5,253)
Residual cash flows (6,700) (3,405)     108 (1,412) (10,492)
 
M2001 FLCS pre-seen13
Appendix F
Molecular Allies
Profit and loss accounts for the years ended 31 December 1996 – 2000 (unpublished)
These accounts are prepared on the same basis as Appendix D
1996 1997 1998 1999 2000
Actual Actual Actual Actual Actual
e000 e000 e000 e000 e000
Sales 3,591 5,053 7,110 10,003 14,075
Cost of sales (1,229) (1,822) (2,703) (4,010) (5,948)
Gross profit 2,362 3,231 4,407 5,993 8,127
Research and development 0 0 0 (80) (232)
Administrative expenses (2,510) (3,432) (4,681) (3,258) (9,313)
EBIT (earnings before interest and tax) (148) (201) (274) 2,655 (1,418)
Interest income 79 136 259 242 50
Interest expense  (15)  (14)    (4)      (23)      (62)
EBT (earnings before tax) (84) (79) (19) 2,874 (1,430)
Taxation payable  (45)  (85) (78)   (341)    107
Earnings after tax (129) (164) (97) 2,533 (1,323)
 
Appendix G
Molecular Allies
Statement of cash flows 1996 – 2000 (unpublished)
These accounts are prepared on the same basis as Appendix E
1996 1997 1998 1999 2000
Actual Actual Actual Actual Actual
e000 e000 e000 e000 e000
EBIT (earnings before interest and tax) (148) (201) (274) 2,655 (1,418)
Interest income (expense)   64 122 255    219     (12)
Pre-tax profit (84) (79) (19) 2,874 (1,430)
Taxes   (45)   (85)   (78)   (341)    107
Net income (129) (164) (97) 2,533 (1,323)
Depreciation 75 102 128 255 689
Amortisation 0 0 0 264 1,557
Capital expenditures (142) (119) (148)   (290) (817)
Residual cash flows (196) (181) (117) 2,762 106
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Appendix H:
Molecular Allies Division – publicly announced projects
Collaborator /
Partner
Project Start
year
Details
BioCell3 (Multi-disciplinary discovery) 1996 Proton Quest (PQ) does in-house design
work and outsources chemistry and
biology to university researchers.
Panda
Pharmaceuticals
(Combinations library designs
& synthesis)
1997 PQ provides molecular modelling
techniques to design novel targeted
combinations libraries which Molecules4U
Combinations will synthesise. An
important aspect of this collaboration is
the training and transfer of technical skills
to Panda staff.
Immune2Day (Antibody humanisation) 1995
to
1997
Immune2Day got exclusive rights to the
antibody technology. PQ got payment and
rights to use Immune2Day's antibody
technology outside of the latter's
specialist field, oncology.
Transform-Motif
Corp
(Drug design & combinations
chemistry)
1998 PQ and Molecules4U Combinations will
"identify novel lead compounds for the
treatment of metabolic disorders" (Proton
Quest).
RXRibo (Computational – antibody
humanisation)
1993 Humanised antibody component of a
radio-immunotherapy product to localise
antibodies at tumour sites. The drug is
now in phase II clinical trials.
Medical Sylapion (Drug design, combinations
chemistry & HTS)
1998 PQ will use its software and discovery
skills to design multiple libraries.
Molecules4U Combinations will provide
synthesis of the libraries. Molecules4U
Drug Discovery will provide High
Throughput Screening (HTS) and
consultancy services for Medical
Sylapion's internal discovery process.
Bonded Sol (Computer Aided Molecular
Design : CAMD)
1997 PQ to provide drug design services to
enable Bonded Sol to develop a blood
growth factor free of third-party patent
hindrances.
Cascade Org (Computer Aided Molecular
Design : CAMD)
1996 Targeting drugs to treat cancer. Cascade
Org contributes HTS of chemical libraries
and directed drug design methods.
Ionic Tiger (Multi-disciplinary discovery) 1996 Discovery of a novel drug candidate,
based on Ion channels with the potential
to target multiple diseases.  The project is
managed by PQ, with much of the work
outsourced to university researchers.
 Source: Proton Quest press releases
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Appendix I:
Molecules4U Combinations Ltd (private, unlisted partner company)
Foundation
The company was founded in January 1998 by a group of top scientists and professors from two
leading universities. In 1998, Proton Quest invested e2 million for a 19.99% shareholding. The other
shareholders are the senior management, including Eric Smyth, CEO (a former colleague of Dr
Martin Hislop, CEO of Proton Quest) and Molecules4U University, which provided intellectual
property rights.  This is a trade investment.
Technology
The company takes a medicinal chemistry approach to drug discovery, providing chemical
synthesis services. It specialises "in the design, production and supply of chemical structures for
the drug discovery industry" (Proton Quest). It can produce "moderately sized libraries of up to
20,000 compounds in a pure, well-characterised reproducible form. Milligram batches of each
component in a library will be produced at the same time to provide the end user with sufficient
material for every stage of testing" (Proton Quest). Such libraries play a crucial role in generating a
pool of compounds from which novel lead compounds can be identified.
Commercial offering
Combinations chemistry services, consultancy, and technology transfer.
Collaborative relationship with Proton Quest
Molecules4U Combinations plays an important role in Proton Quest's long-term aim of providing
one-stop shopping for drug discovery services. This goal requires four capabilities, two of which are
chemical synthesis and combinations libraries (Annual Report 1998). The Molecular Allies division
manages projects which identify novel drug targets to which Molecules4U Combinations'
technology can be applied to generate a library of potential lead compounds. In turn, Proton
Quest's (and partners') capabilities in screening chemical libraries and rational drug design enable
these leads to be optimised before entering clinical trials.
Deals to date
Molecules4U Combinations has combined with the Molecular Allies division in three important
alliances. The first aims to provide combinations library designs and synthesis, including
technology transfer, to Panda Pharmaceuticals. The second alliance is with Medical Sylapion.
This is targeted on "carbohydrate processing enzymes which have potential therapeutic use for
diseases such as fungal infections" (Proton Quest). Molecules4U Combinations provide syntheses
of libraries, which are designed using expertise from Proton Quest, while the libraries are screened
by Molecules4U Drug Discovery. The third collaboration seeks to "identify novel lead compounds
for the treatment of metabolic disorders" for Transform-Motif Corp.
FLCS pre-seen M200116
Appendix J:
Molecules4U Drug Discovery Ltd (private, unlisted partner company)
Foundation
The company was founded in January 1998 by four leading scientists. e8.2 million was raised from
investors, primarily Proton Quest, which invested e6.0 million: e3.3 million in return for a 19.99%
shareholding, and e2.7 million in preference shares. If Molecules4U Drug Discovery is floated, or
sold, then the preference shares convert into a 10.1% shareholding. Proton Quest has the option,
exercisable between the years 2000 and 2002, to purchase the remaining ordinary shares for the
greater of 3 times turnover, or 15 times net profit.  This is a trade investment.
Technology
High Throughput Screening (HTS), the company's core technology, enables researchers to screen
libraries of molecule compounds against biological targets (such as proteins) to determine how
potentially potent, selective and bio-available the compounds are as a new drug candidate.
Biological screening, using HTS, is central to the task of identifying novel lead compounds.
These libraries can contain millions of compounds, hence automation is essential in the screening
process. Molecules4U Drug Discovery has invested in robotics systems which enable the
company to "screen up to 100,000 compounds a day from customers' own libraries of chemical
compounds against either novel or non-proprietary targets" (Proton Quest).
Commercial offering
The company can screen libraries for customers in addition to the design of chemical assays and
HTS consultancy.
Collaborative relationship with Proton Quest
Many of the company's products will be sold via collaborative projects with Proton Quest. Third-
party sales will be through Proton Quest's distribution system, for which Molecules4U Drug
Discovery pays a percentage of the overheads. As outlined in Proton Quest's Annual Report
(1997), HTS is one of the four capabilities needed to achieve the group's goal of becoming a one-
stop-shop provider of drug discovery services. The Molecular Allies division manages projects
which identify novel drug targets to which Molecules4U Drug Discovery's HTS technology can be
applied to generate lead compounds. In turn, Proton Quest's capabilities in rational drug design
enable these leads to be optimised before entering clinical trials.
Deals to date
The Molecular Allies division of Proton Quest, in co-operation with Molecules4U Drug Discovery
and Molecules4U Combinations, is managing a drug discovery programme targeting fungal
infections for Medical Sylapion. Molecules4U Drug Discovery will screen the libraries which Proton
Quest designs and develops, with Molecules4U Combinations conducting the synthesis of those
libraries.
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Appendix K
Additional information
INDUSTRY BACKGROUND
The pharmaceutical industry and the context within which Proton Quest operates
Modern biotechnology came to life with the discovery of DNA (deoxyribonucleic acid), which can
be simply thought of as the blueprint of life (BIO, 1999). Three advances made the manipulation of
DNA, and hence modern biotechnology, a practical reality.  These were hybridoma technology,
discovered by Kohler and Milstein in 1975 (Faulkner, Senker, and Velho, 1995), Recombinant
DNA (rDNA), discovered by Boyer and Cohen in 1973 at Stanford University (Faulkner, Senker,
and Velho, 1995) and Protein Engineering (Oxender and Graddis, 1991).
Further advances in molecular biology have enabled companies to gain a much greater
understanding of biological organisms and how they can be manipulated to improve human health,
crop yields and environmental protection. The application of modern biotechnology spans four
important sectors in the world economy, namely:
· discovery and development of therapeutic drugs to improve treatment of human diseases;
· diagnostics tools to identify human and animal diseases;
· agricultural biotechnology, which involves the genetic modification of plants and animals with
the goal of improving yields and nutrition; and
· environmental protection, such as clean up of hazardous wastes (BIO, 1999; Ernst and
Young, 1999).
Although the importance, in terms of potential contribution, of biotechnology to our society is
immense, this industry, especially in the European sector, is still in its embryonic stage. As a
result, many companies which comprise this sector are many years away from significant
revenues generated by sales of drugs. For example, until recently there was only one
biotechnology company in the UK approved for marketing a drug: that is, Chirocaine, by Celltech-
Chiroscience. With a lack of real earnings to fund R&D expenditures, independent biotechnology
companies in Europe have relied primarily on two sources of cash. These sources consist of (i)
funds raised from stakeholders, and (ii) revenues raised through collaborative agreements, with
equity funding being the primary source of capital for companies in their early stage of
development. Although for biotechs the amount of capital raised via stakeholders has declined in
the US over recent years, it has risen in Europe, thus suggesting the perceived importance of the
European biotechnology sector.
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Table One:
The drug discovery process
The goal of the drug discovery process is to create a drug compound, targeted at a specific
disease, which can enter regulatory clinical trials. Should the drug successfully pass through the
regulatory process, then it can be marketed. At the heart of the Proton Quest approach to drug
discovery is an embrace of both traditional drug discovery and computer-based rational drug
design. The difference between the two approaches is that rational drug design seeks "to model
the molecular structure of the target of a drug, and then design a drug molecule which will fit it.
This contrasts with the alternative, which is to screen a large number of compounds for drug
activity, choose the most promising and make a whole lot of variants, choose the most promising
of them and repeat until a suitable drug is found" (Bains 1993).
In practice, it is not possible to create a drug compound employing computer methods alone.
Thus, Proton Quest offers its customers a combination of software to facilitate rational drug
discovery, in addition to managerial skills and experience in the blending of this technique with
traditional methods of screening and discovery.
There are four broad stages to a drug discovery process, three of which Proton Quest is actively
involved in. The first is the identification of a target disease. Targets may be selected on the basis
of specialist knowledge about the disease within a company, the potential market rewards of
pursuing a treatment, and/or new advances in technology which offer potential application in a
targeted disease area. Targeting a disease is generally the domain of Proton Quest's clients.
Second is identification of biological targets. These are proteins or genes which the
researchers believe play an important role in the spread of the target disease. The researchers
seek to understand what form of compound would be needed to interact with the protein or gene
which is causing the disease and thus manage or cure it.
Third is lead compound identification. This involves identifying compounds which are
biologically active against the biological target.
Fourth is lead optimisation, or refinement. Having identified a number of biologically-active
compounds, it is necessary to determine which of these has the best mix in terms of activity, with
the lowest level of toxicity.
 
Table Two:
Bio-informatics – the identification of biological targets
"Bio-informatics is the use of software, databases and on-line resources to store, retrieve and
analyse genomic information (such as information on human genes). Analysis of genomic
information enables suitable biological targets to be identified in order to discover new drugs which
may halt the disease or control the infection" (Proton Quest Annual Report 1997).
 Bio-informatics software produced by Proton Quest is used by researchers as "tools for the
analysis of DNA and protein sequence data" (Proton Quest).  Bio-informatics tools play a central
role in the identification of biological targets.
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Table Three:
Chemo-informatics – the identification of lead compounds
Chemo-informatics builds upon the process of identifying biological targets (central to which is Bio-
informatics) with the goal of identifying lead compounds.
Chemo-informatics software tools enable researchers to "capture, analyse and communicate the
increasing volumes of biological and chemical data available in the search for new lead compounds
and drug candidates" (Proton Quest Annual Report 1997). These tools are used for "selecting,
comparing, relating, mining data for databases of chemical compounds, structures, properties and
biological assay results" (Proton Quest).
Examples of Chemo-informatics software available from Proton Quest include RS3 TM Discovery
(which is used for "storing, searching and retrieval of chemical structures in addition to chemical
and biological properties, experimental data and registration" Proton Quest), and DIVA TM (a
spreadsheet-based product to facilitate the visualisation and analysis of chemical structures).
Table Four:
Computer Aided Molecular Design (CAMD) – lead optimisation
Lead optimisation involves analysing the compound to discover its potential biological activity
and toxicity. When a lead compound is identified, it still remains to be proven whether this
compound can be safely applied to humans, and whether it successfully tackles the disease. The
compound may well need to be structurally modified to enable it to combat the disease both safely
and effectively. Once the researchers have modified the lead compound, it must then be entered
into clinical trials before it can be marketed. These trials can cost hundreds of millions of Euros. If
the compound fails in trials, then it cannot be sold to the public. It is, therefore, vital that the
process of lead optimisation discovers potential problems with the compound, and solves them
prior to entering into clinical trials. CAMD greatly enhances the efficiency and effectiveness of the
lead optimisation process when compared to older, conventional screening techniques.
"In the past this {lead optimisation} involved random chemical synthesis around a particular lead
structure with known, but inadequate, biological properties. …. {CAMD} allow{s} a more rational
approach whereby a research scientist can visualise a compound's structure through molecular
modelling and explore structural modifications to improve its desired properties" (Proton Quest
Annual Report 1997).
CAMD tools are "used both by computational and experimental chemists to predict reaction
mechanisms and explain interactions, speeding up the identification of compounds with desirable
properties".  (Proton Quest)
Table 5:
Genomics
Genomics is the identification of the genetic basis for disease, which relates to the information
encoded by DNA.  The study of genomes, which includes genome mapping, gene sequencing and
function, is often linked to the search for genes which are associated with disease.
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